Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cisatracurium besilate, quantity: 211.05 mg (equivalent: cisatracurium, qty 157.5 mg) - injection, solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cisatracurium besilate, quantity: 14.07 mg (equivalent: cisatracurium, qty 10.5 mg) - injection, solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cisatracurium besilate, quantity: 28.14 mg (equivalent: cisatracurium, qty 21 mg) - injection, solution - excipient ingredients: water for injections; benzenesulfonic acid - cisatracurium injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cisatracurium besilate, quantity: 7.04 mg - injection, solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

United States - English - NLM (National Library of Medicine)

jiangsu hengrui medicine co., ltd. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium 2 mg in 1 ml - cisatracurium besylate injection is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate injection is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium have been reported [see warnings and precautions ( 5.4)] . the use of 10 ml cisatracurium multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains benzyl alcohol [see warnings and

United States - English - NLM (National Library of Medicine)

mylan institutional llc - atracurium besylate (unii: 40ax66p76p) (atracurium - unii:2gq1iry63p) - atracurium besylate 10 mg in 1 ml - atracurium besylate injection, usp is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. atracurium besylate is contraindicated in patients known to have a hypersensitivity to it. use of atracurium besylate from multiple dose vials containing benzyl alcohol as a preservative is contraindicated in patients with a known hypersensitivity to benzyl alcohol.

United States - English - NLM (National Library of Medicine)

jiangsu hengrui medicine co., ltd. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium 2 mg in 1 ml - cisatracurium besylate injection is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate injection is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium have been reported [see warnings and precautions ( 5.4)] . the use of 10 ml cisatracurium multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains benzyl alcohol [see warnings and

United States - English - NLM (National Library of Medicine)

sandoz inc - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium 2 mg in 1 ml - cisatracurium besylate injection is indicated: limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate injection is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium besylate have been reported [see warnings and precautions (5.4)] . risk summary there are no adequate and well-controlled studies of cisatracurium besylate in pregnant women. animal studies conducted in rats administered cisatracurium besylate during organogenesis found no evidence of fetal harm at 0.8 times (ventilated rats) the exposure from a human starting iv bolus dose of 0.2 mg/kg. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisatracurium besilate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisatracurium besilate -